Zefeng Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zefeng Shen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Bangsheng Chen
Emergency Medical Center, Ningbo Yinzhou No 2 Hospital, Ningbo, Zhejiang, China
2 shared publications - Feiyan Mao
Department of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China
2 shared publications - Lihu Gu
Department of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China
2 shared publications - Parikshit Asutosh Khadaroo
Neuropsychiatry & ECT Department, Royal Melbourne Hospital, Grattan Street Parkville, Melbourne, VIC 3052, Australia
2 shared publications - Xianfa Wang
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
2 shared publications - Bin Zhou
Department of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 9 June 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (S2) , 803
A HYBRID ENERGY‐ AND AI‐BASED SCREENING FOR NOVEL INHIBITORS OF LCK FOR THE TREATMENT OF T‐CELL LYMPHOBLASTIC LYMPHOMA
- 9 June 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (S2) , 803
Open AccessA HYBRID ENERGY‐ AND AI‐BASED SCREENING FOR NOVEL INHIBITORS OF LCK FOR THE TREATMENT OF T‐CELL LYMPHOBLASTIC LYMPHOMA
- 26 July 2021
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 21 (14) , 1931-1940
The Efficacy and Safety of Additional Anti-HER2-Targeting Drugs in the Treatment of HER2-Positive Advanced Breast Cancer: A Meta-Analysis
Background: HER2-positive breast cancer patients account for one-fifth of the total breast cancer population. Besides, more and more anti-HER2-targeting drugs have appeared clinically. Objective: This study aimed to analyze the efficacy and safety of additional anti-HER2 (Human Epidermal growth Factor Receptor 2)-targeting drugs in the treatment of HER2-positive advanced breast cancers. Methods: The following databases were searched for published articles containing data on the efficacy and safety of additional anti-HER2- targeting drugs in HER2-positive advanced breast cancer from the time of their inception until December 2019: PubMed, Web of Science, EBSCO, and Cochrane library. The primary outcomes were progression-free survival (PFS) and overall survival(OS). Results: The additional anti-HER2-targeting drugs significantly improved the PFS (HR: 0.66, p<0.001) and OS (HR: 0.77, p<0.001) of HER2-positive advanced breast cancer patients. Regarding drug types, lapatinib was the most effective (HR: 0.53, 95% Cl: 0.39-0.67, p<.001), followed by pertuzumab (HR: 0.72, 95% Cl: 0.55-0.89, p=0.001). Trastuzumab was the least beneficial (HR: 0.87, 95% Cl: 0.31-1.44, p=0.594). Concerning treatment regimen, first-line treatment (HR: 0.67, 95% Cl: 0.52-0.82, p<0.001) was more effective than non-first-line treatment (HR: 0.82, 95% Cl: 0.71-0.94, p=0.004). The main Adverse Events (AEs) observed were diarrhea and decreased ejection fraction. Conclusion: Additional anti-HER2-targeting drugs can improve long-term prognosis in HER2-positive advanced breast cancers. Besides, they are associated with fewer AEs and are tolerable. Lapatinib is the most effective drug, followed by pertuzumab, whereas trastuzumab is the least effective. Concerning treatment, we recommend the use of anti-HER2-targeting drugs in first-line therapy of HER2-positive advanced breast cancers.
- 26 July 2021
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 21 (14) , 1931-1940
The Efficacy and Safety of Additional Anti-HER2-Targeting Drugs in the Treatment of HER2-Positive Advanced Breast Cancer: A Meta-Analysis
Background: HER2-positive breast cancer patients account for one-fifth of the total breast cancer population. Besides, more and more anti-HER2-targeting drugs have appeared clinically. Objective: This study aimed to analyze the efficacy and safety of additional anti-HER2 (Human Epidermal growth Factor Receptor 2)-targeting drugs in the treatment of HER2-positive advanced breast cancers. Methods: The following databases were searched for published articles containing data on the efficacy and safety of additional anti-HER2- targeting drugs in HER2-positive advanced breast cancer from the time of their inception until December 2019: PubMed, Web of Science, EBSCO, and Cochrane library. The primary outcomes were progression-free survival (PFS) and overall survival(OS). Results: The additional anti-HER2-targeting drugs significantly improved the PFS (HR: 0.66, p<0.001) and OS (HR: 0.77, p<0.001) of HER2-positive advanced breast cancer patients. Regarding drug types, lapatinib was the most effective (HR: 0.53, 95% Cl: 0.39-0.67, p<.001), followed by pertuzumab (HR: 0.72, 95% Cl: 0.55-0.89, p=0.001). Trastuzumab was the least beneficial (HR: 0.87, 95% Cl: 0.31-1.44, p=0.594). Concerning treatment regimen, first-line treatment (HR: 0.67, 95% Cl: 0.52-0.82, p<0.001) was more effective than non-first-line treatment (HR: 0.82, 95% Cl: 0.71-0.94, p=0.004). The main Adverse Events (AEs) observed were diarrhea and decreased ejection fraction. Conclusion: Additional anti-HER2-targeting drugs can improve long-term prognosis in HER2-positive advanced breast cancers. Besides, they are associated with fewer AEs and are tolerable. Lapatinib is the most effective drug, followed by pertuzumab, whereas trastuzumab is the least effective. Concerning treatment, we recommend the use of anti-HER2-targeting drugs in first-line therapy of HER2-positive advanced breast cancers.
- Open Access
- 1 January 2020
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 15 (1) , 754-762
Prognostic factors in stage I gastric cancer: A retrospective analysis
Purpose: The purpose of this research is to investigate the prognostic factors of patients with stage I gastric cancer (GC) and to determine whether adjuvant chemotherapy improves the prognosis for high-risk patients. Methods: We performed a retrospective analysis at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and HwaMei Hospital, University of Chinese Academy of Sciences from January 2001 to December 2015. Cox regression and Kaplan-Meier were used to evaluate the relationship between the patients’ clinicopathologic characteristics and prognosis. Results: A total of 1,550 patients were eligible for the study. The 5-year disease-free survival (DFS) rate of all enrolled patients was 96.5%. The pT and pN stages were significantly associated with the prognosis. The 5-year DFS rates of the three subgroups (T1N0, T2N0, and T1N1) were 97.8%, 95.7%, and 90.5%, respectively (p < 0.001). In the T1N1 subgroup, patients not undergoing chemotherapy showed a lower 5-year DFS rate compared to those undergoing chemotherapy, although the difference was not statistically significant. Conclusions: Both the pT and pN stages were closely associated with the prognosis of patients with stage I GC. We also found that the danger coefficient of the pN stage was higher than that of the pT stage, and that postoperative adjuvant chemotherapy might be a reasonable approach to improve outcomes of high-risk patients, particularly in the T1N1 group.
- 1 January 2020
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 15 (1) , 754-762
Open AccessPrognostic factors in stage I gastric cancer: A retrospective analysis
Purpose: The purpose of this research is to investigate the prognostic factors of patients with stage I gastric cancer (GC) and to determine whether adjuvant chemotherapy improves the prognosis for high-risk patients. Methods: We performed a retrospective analysis at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and HwaMei Hospital, University of Chinese Academy of Sciences from January 2001 to December 2015. Cox regression and Kaplan-Meier were used to evaluate the relationship between the patients’ clinicopathologic characteristics and prognosis. Results: A total of 1,550 patients were eligible for the study. The 5-year disease-free survival (DFS) rate of all enrolled patients was 96.5%. The pT and pN stages were significantly associated with the prognosis. The 5-year DFS rates of the three subgroups (T1N0, T2N0, and T1N1) were 97.8%, 95.7%, and 90.5%, respectively (p < 0.001). In the T1N1 subgroup, patients not undergoing chemotherapy showed a lower 5-year DFS rate compared to those undergoing chemotherapy, although the difference was not statistically significant. Conclusions: Both the pT and pN stages were closely associated with the prognosis of patients with stage I GC. We also found that the danger coefficient of the pN stage was higher than that of the pT stage, and that postoperative adjuvant chemotherapy might be a reasonable approach to improve outcomes of high-risk patients, particularly in the T1N1 group.
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gastric Cancer
- Vol. 20 (1) , 81-94
Risk Factors for Duodenal Stump Leakage after Laparoscopic Gastrectomy for Gastric Cancer
Gu L, et al. J Gastric Cancer. 2019 Sep;20:e4. https://doi.org/10.5230/jgc.2020.20.e4
- 1 January 2020
- Published by XMLink in Journal of Gastric Cancer
- Vol. 20 (1) , 81-94
Open AccessRisk Factors for Duodenal Stump Leakage after Laparoscopic Gastrectomy for Gastric Cancer
Gu L, et al. J Gastric Cancer. 2019 Sep;20:e4. https://doi.org/10.5230/jgc.2020.20.e4